Welcome to our dedicated page for Aim Immunotech SEC filings (Ticker: AIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a 300-page biotech disclosure filled with immunology jargon is no small feat—especially when AIM ImmunoTech’s next Ampligen trial update could reshape its valuation overnight. If you have ever searched “AIM ImmunoTech SEC filings explained simply” or wondered how to spot insider confidence before data readouts, this page is built for you.
Stock Titan’s platform translates every 10-K annual report, 10-Q quarterly earnings report, and 8-K material event into plain-English highlights. Our AI pinpoints where R&D expenses spike, flags new FDA correspondence, and surfaces patent portfolio changes, saving hours normally spent scrolling through dense exhibits. Need real-time alerts? Get “AIM ImmunoTech Form 4 insider transactions real-time” within minutes of filing so you can track executive stock transactions before the market reacts.
Each filing answers a different investor question:
- The “AIM ImmunoTech annual report 10-K simplified” section shows Ampligen trial timelines and cash runway.
- The “AIM ImmunoTech quarterly earnings report 10-Q filing” reveals burn rate shifts between oncology and antiviral programs.
- “AIM ImmunoTech proxy statement executive compensation” uncovers how leadership is rewarded for clinical milestones.
- “AIM ImmunoTech insider trading Form 4 transactions” captures buying or selling that may precede pivotal data.
- “AIM ImmunoTech 8-K material events explained” highlights fresh trial results, licensing deals, or FDA designations.
From monitoring cash runway to understanding AIM ImmunoTech earnings report filing analysis, our AI-powered summaries distill what matters so you can make informed decisions faster.
AIM ImmunoTech Inc. (NYSE American: AIM) has filed Amendment No. 1 to its Form S-3 shelf registration statement, seeking authorization to issue up to $100 million of securities. The registration covers a wide variety of instruments—including common and preferred stock, debt securities (senior, senior subordinated or subordinated, convertible or non-convertible), warrants, purchase contracts, subscription rights, depositary shares and units—allowing management to access capital “from time to time” and in multiple tranches.
The company is classified as a non-accelerated filer and a smaller reporting company; it is not an emerging growth company. AIM’s common stock last traded at $9.50 on 23 June 2025. Specific terms (pricing, size, use of proceeds, underwriting arrangements) will be detailed in future prospectus supplements when individual offerings are launched.
Because the filing is a shelf registration under Rule 415, the statement enables AIM to move quickly when market conditions are favorable. However, the document also cautions investors that the information is preliminary and subject to change until the SEC declares the registration effective. Standard risk disclosures and forward-looking-statement safe-harbor language are included, and investors are directed to the company’s latest 10-K and subsequent filings for detailed risk factors.
Key takeaways for investors:
- Financing flexibility: Up to $100 million aggregate offering amount across multiple security types.
- Dilution potential: Common-equity issuance could dilute existing shareholders, depending on the mix ultimately chosen.
- Timing unknown: Securities may be issued “from time to time” after effectiveness; no immediate issuance timetable is provided.
- No earnings data: The filing does not include current operating results or guidance; it strictly pertains to capital-markets authority.
AIM ImmunoTech received a warning notification from NYSE American on June 17, 2025, regarding non-compliance with minimum stockholders' equity requirements. The company reported a stockholders' deficit of -$3.9 million as of March 31, 2025, falling short of the required:
- $4.0 million minimum for companies with losses in 3 of 4 recent fiscal years
- $6.0 million minimum for companies with losses in 5 most recent fiscal years
This follows a previous warning from December 17, 2024. The NYSE American has accepted AIM's compliance plan, giving the company until June 11, 2026 to meet requirements. Trading continues under symbol "AIM" without interruption, and the warning does not affect business operations or SEC reporting requirements. The company's stock resumed trading on NYSE American on June 17, 2025.
FAQ
What is the current stock price of Aim Immunotech (AIM)?
What is the market cap of Aim Immunotech (AIM)?
What is the core focus of AIM ImmunoTech Inc.?
What are the main therapeutic products developed by AIM ImmunoTech?
How does AIM ImmunoTech position itself within the biopharmaceutical industry?
What is the significance of Ampligen in AIM ImmunoTech’s product portfolio?
How does the company approach clinical research and product development?
What distinguishes AIM ImmunoTech from other companies in the immuno-pharma sector?
